Frequently asked questions

"iTind" is short for temporary implantable nitinol device. Nitinol is a shape-memory nickel-titanium alloy commonly used in endoscopic and vascular devices.

About 5 to 7 days. It is placed on one day and removed at a second short visit, usually in a day-surgery or outpatient setting.

A urinary catheter is generally not required during the iTind wear period; you pass urine normally around the device. Your urologist will advise you if your individual situation differs.

Some men experience mild pelvic discomfort, urinary urgency or occasional blood-tinged urine during the wear period. Severe pain is not expected and should prompt contact with the rooms. Your team will give you appropriate analgesia and antispasmodics.

Published studies focused on sexual function after iTind report preservation of erectile and ejaculatory function in the treated patients.^{3, 4} Individual outcomes still vary; your urologist will discuss what to expect in your case.

Many men return to office-style work within a few days of insertion. Heavy manual work and strenuous exercise are usually delayed until after device removal. Your rooms team will give you a tailored timeline.

Rezum uses water vapour to treat prostate tissue, which is then reabsorbed. UroLift places permanent implants to hold prostate lobes apart. iTind uses a temporary nitinol device that is removed after 5 to 7 days and does not leave an implant behind. See the comparison table on the candidacy page.

In Australia iTind is usually performed as day surgery - both insertion and removal. Some patients, based on health or social circumstances, may need a short stay.

iTind does not preclude later BPH treatments. If symptoms return, your urologist can reassess and consider medication, another minimally invasive option, or a definitive surgical procedure such as Holmium laser enucleation or TURP.

Medicare and private insurance coverage depend on item numbers, your policy and the hospital setting. Ask the rooms for a written estimate of fees and gap, and check with your fund whether your policy covers the specific item numbers involved.

The device is available in Australia through its local distributor. The Therapeutic Goods Administration (TGA) ARTG listing and instructions for use are the authoritative technical source; your treating team can confirm current status at the time of your consultation.

Once the device is removed there is no implant left in the body, so subsequent MRI is treated the same way as for any other patient. During the wear period, consult your treating team if MRI is being proposed.

Yes. Many men ask another specialist to review their scans, flow results and suggested plan. See the second opinion page for what to send.

Phone, email and addresses are on the contact page.